Jiang Zhong, Woda Bruce A
Department of Pathology, University of Massachusetts Medical School, Worcester, Massachusetts 01655, USA.
Adv Anat Pathol. 2004 Nov;11(6):316-21. doi: 10.1097/01.pap.0000146924.14246.be.
Alpha-methylacyl CoA racemase (AMACR), also known as P504S, was identified by the analysis of cDNA library subtraction in conjunction with high throughput microarray screening from prostate tissue and has been proven to be one of the very few biomarkers that can distinguish cancer from benign cells with high sensitivity and specificity for prostate carcinoma. It is a successful example of the translation of molecular findings into clinical practice. This review focuses on the study of AMACR (P504S) expression in small focal prostate cancer and atypical small acinar proliferation (ASAP) on needle biopsies and emphasizes the utility of AMACR (P504S) in routine surgical pathology practice. We also discuss the potential pitfalls and caveats in the interpretation of immunostaining results.
α-甲基酰基辅酶A消旋酶(AMACR),也称为P504S,是通过对前列腺组织的cDNA文库消减分析结合高通量微阵列筛选鉴定出来的,并且已被证明是极少数能够以高灵敏度和特异性区分前列腺癌癌细胞与良性细胞的生物标志物之一。它是将分子研究结果转化为临床实践的一个成功范例。本综述着重于研究针吸活检中微小局灶性前列腺癌和非典型小腺泡增生(ASAP)中AMACR(P504S)的表达,并强调AMACR(P504S)在常规外科病理学实践中的应用。我们还讨论了免疫染色结果解读中潜在的陷阱和注意事项。